Now showing items 1-6 of 6

    • A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells 

      Duan, Zhenfeng; Zhang, Jianming; Ye, Shunan; Shen, Jacson; Choy, Edwin; Cote, Gregory; Harmon, David; Mankin, Henry; Hua, Yingqi; Zhang, Yu; Gray, Nathanael S; Hornicek, Francis J (BioMed Central, 2014)
      Background: Reversing multidrug resistance (MDR) has been an important goal for clinical and investigational oncologists. In the last few decades, significant effort has been made to search for inhibitors to reverse MDR ...
    • CD44 is a direct target of miR-199a-3p and contributes to aggressive progression in osteosarcoma 

      Gao, Yan; Feng, Yong; Shen, Jacson K.; Lin, Min; Choy, Edwin; Cote, Gregory M.; Harmon, David C.; Mankin, Henry J.; Hornicek, Francis J.; Duan, Zhenfeng (Nature Publishing Group, 2015)
      Osteosarcoma is the most common primary bone malignancy in children and adolescents. Herein, we investigated the role of cluster of differentiation 44 (CD44), a cell-surface glycoprotein involved in cell-cell interactions, ...
    • Expression of programmed cell death ligand 1 (PD-L1) and prevalence of tumor-infiltrating lymphocytes (TILs) in chordoma 

      Feng, Yong; Shen, Jacson; Gao, Yan; Liao, Yunfei; Cote, Gregory; Choy, Edwin; Chebib, Ivan; Mankin, Henry; Hornicek, Francis; Duan, Zhenfeng (Impact Journals LLC, 2015)
      Chordomas are primary malignant tumors of the notochord that are resistant to conventional chemotherapy. Expression of programmed cell death ligand 1 (PD-L1), prevalence of tumor-infiltrating lymphocytes (TILs), and their ...
    • Genotyping Cancer-Associated Genes in Chordoma Identifies Mutations in Oncogenes and Areas of Chromosomal Loss Involving CDKN2A, PTEN, and SMARCB1 

      Choy, Edwin; MacConaill, Laura E.; Cote, Gregory M.; Le, Long P.; Shen, Jacson K.; Nielsen, Gunnlaugur P.; Iafrate, Anthony J.; Garraway, Levi A.; Hornicek, Francis J.; Duan, Zhenfeng (Public Library of Science, 2014)
      The molecular mechanisms underlying chordoma pathogenesis are unknown. We therefore sought to identify novel mutations to better understand chordoma biology and to potentially identify therapeutic targets. Given the ...
    • Opposing Immune and Genetic Mechanisms Shape Oncogenic Programs in Synovial Sarcoma 

      Jerby-Arnon, Livnat; Neftel, Cyril; Shore, Marni E.; Weisman, Hannah R.; Mathewson, Nathan; McBride, Matthew J.; Haas, Brian; Izar, Benjamin; Volorio, Angela; Boulay, Gaylor; Cironi, Luisa; Richman, Alyssa R.; Broye, Liliane C.; Gurski, Joseph M.; Luo, Christina; Mylvaganam, Ravindra; Nguyen, Lan; Mei, Shaolin; Melms, Johannes; Georgescu, Christophe; Cohen, Ofir; Buendia Buendia, Jorge Eduardo; Segerstolpe, Asa; Sud, Malika; Cuoco, Michael; Labes, Danny; Zollinger, Daniel R.; Ortogero, Nicole; Beechem, Joseph M.; Nielsen, G. Petur; Chebib, Ivan; Nguyen-Ngoc, Tu; Montemurro, Michael; Cote, Gregory; Choy, Edwin; Letovanec, Igor; Cherix, Stéphane; Wagle, Nikhil; Sorger, Peter; Haynes, Alex; Mullen, John; Stamenkovic, Ivan; Rivera, Miguel; Kadoch, Cigall; Wucherpfennig, Kai; Rozenblatt-Rosen, Orit; Suvà, Mario L.; Riggi, Nicolò; Regev, Aviv (Cold Spring Harbor Laboratory, 2021-01-25)
      <jats:title>ABSTRACT</jats:title><jats:p>Synovial sarcoma is an aggressive mesenchymal neoplasm, driven by the SS18-SSX fusion, and characterized by immunogenic antigens expression and exceptionally low T cell infiltration ...
    • Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy 

      Choy, Edwin; Butrynski, James E; Harmon, David C; Morgan, Jeffrey A; George, Suzanne; Wagner, Andrew J; D’Adamo, David; Cote, Gregory M; Flamand, Yael; Benes, Cyril H; Haber, Daniel A; Baselga, Jose M; Demetri, George D (BioMed Central, 2014)
      Background: Preclinical studies have documented antitumor activity of PARP inhibition both in vitro and in vivo, against Ewing sarcoma cells. This study aimed to translate that observation into a clinical trial to assess ...